Skip to main content
. 2022 May 6;8(1):e002031. doi: 10.1136/rmdopen-2021-002031

Table 2.

Treatment use in 13 countries in 410 patients, grouped by GDP/capita

Overall
(N=410)
Patients in lowest country GDP/capita tertile
(N=101)
Patients in middle country GDP/capita tertile
(N=180)
Patients in highest country GDP/capita tertile
(N=129)
P value between the tertiles
bDMARDs use, n (%) 250 (61.0) 54 (53.5) 113 (62.8) 83 (64.3) 0.197
csDMARDs use, n (%) 237 (61.4) 67 (72.8) 93 (54.7) 77 (62.1) 0.016
Methotrexate use, n (%) 200 (52.2) 57 (63.3) 79 (46.5) 64 (52.0) 0.035
Oral glucocorticoids use, n (%) 64 (17.5) 21 (25.6) 19 (11.6) 24 (20.0) 0.016
High or moderate disease activity (DAPSA >14) and no bDMARD use, n (%) 76 (18.5) 30 (29.7) 27 (15.0) 19 (14.7) 0.004*

Lowest country GDP/capita tertile: Brazil, Turkey, Russian Federation, Romania, Estonia; middle tertile: Spain, Italy, UK, France; highest tertile: Canada, Germany, USA and Singapore.

Data were missing for glucocorticoids (n=44), csDMARDs (n=24) and methotrexate (n=27). Percentages are percentages of available data.

*Specific comparisons were made between tertiles: lowest vs middle (p=0.009), lowest vs highest (p=0.007), middle vs highest (p=0.882).

bDMARDs, biological disease-modifying antirheumatic drugs; csDMARDs, conventional synthetic DMARDs; DAPSA, Disease Activity in PSoriatic Arthritis; GDP, gross domestic product.